Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
A new diagnostic method that ascertains if a person is suffering from Parkinson’s disease or dementia by looking at the manner of walking has been patented.
A new diagnostic technique developed by a St. Mary's Hospital research team in Uijeongbu has been patented and put up for patent registration, which analyses data from an individual's shoes to detect neurological disorders.
Most degenerative brain disorders, such as Parkinson's disease, dementia, and Lou Gehrig's disease, occur at an older age.
Currently, a costly MRI or a PET scan is required for such diagnosis, as well as frequent visits to the hospital.
The new approach, on the other hand, employs a "smart insole" that is placed inside a shoe and collects data from its sensors, which is then analyzed to assess the brain health of the wearer.
The new technique achieved an accuracy of 98.1 percent for the diagnosis of Parkinson's disease, as well as 83.2 percent for differentiating whether an illness is vascular or degenerative.
